◆ 会议时间：2023年5月11日至13日
◆ 会议地点：德国 柏林（Berlin, Germany）
◆ 会议简介：
2023年欧洲肿瘤内科学会(ESMO)乳腺癌大会(年会)将于2023年5月11日至13日在德国柏林举行。ESMO乳腺癌年会是在欧洲举行的一个多学科全球会议，由全球公认的一流专家参与，是所有对创新、转化肿瘤学和护理感兴趣的乳腺癌研究人员和临床医生的进行交流的平台，预计有超过800名专业人士出席会议。
欧洲肿瘤内科学会（ESMO）成立于1975年，是欧洲领先的肿瘤内科学专业组织，现在全球150多个国家和地区拥有超过23,000名会员，是肿瘤学教育和信息的参考学会，ESMO致力于支持其会员在快速发展的专业环境中得到宣发展与进步。作为一个非营利组织，ESMO一直以推动癌症护理和治疗为使命，致力于推进肿瘤医学专业的发展，以多学科的方法来促进癌症的治疗和护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.
ESMO BREAST CANCER CONGRESS 2023
Date: 11-13 May 2023
Venue: Messe Berlin, Berlin, Germany
ESMO Breast Cancer 2023 will take place on 11-13 May 2023 in Berlin, Germany.
Cancer patients and their needs are at the heart of what we do – we are committed to advancing research and integrating it into the clinic to ensure better care for our patients.
We aim to deliver a comprehensive overview of all the practice-changing new data and to make sure it has a clear roadmap to the clinic.
We count on you to take part and we look forward to welcoming you once again to ESMO Breast Cancer, a multidisciplinary meeting where you will learn how to integrate innovation into your daily practice and improve patient care.
摘要征文投稿：
Abstract submission deadlines
*A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline 21 February 2023.
Final versions must be submitted by Wednesday, 12 April 2023 at 21:00 CEST (Central European Summer Time).
Outcome notifications
Outcome notifications are expected to be made available to first authors and submitters by end-March 2023.
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Adjuvant therapy
- Early breast cancer: Neoadjuvant therapy
- Early breast cancer: Surgery and radiotherapy
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Breast Cancer 2023.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 21 February 2023 will be considered for late-breaking status.
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2023.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:
Notes:
- Recruitment must have already begun or have been completed by the abstract submission deadline of 21 February 2023.
- Abstracts including results or preliminary data will be rejected.
- Trial in Progress abstracts will be accepted for Poster outcome only.
- Encore TiP abstracts will be rejected.
Publication schedule of accepted abstracts
Abstracts accepted for presentation during the ESMO Breast Cancer 2023 will be released online according to a schedule which will be available on the ESMO website in due course.
Presentation of accepted abstracts
The Breast Cancer 2023 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Full oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Posters will be displayed for the whole duration of the Congress. Presenting authors must be available for Q&A to represent their work during the 45-minute Poster display session.
Publications
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2023 Abstract Book, a supplement to ESMO Open.
◆ 参会对象：
肿瘤科医师、乳腺外科医师，妇科医师，乳腺科医师，胸外科医师，普外科医师，介入放射科医师，病理科医师，护士以及从事肿瘤护理与研究的其他相关专业人士等。
|
